House dust mite allergy market seen reaching $4.62 billion by 2030

The house dust mite allergy market is projected to grow from $2.37 billion in 2025 to $4.62 billion by 2030, driven by rising asthma cases, broader testing and wider use of immunotherapy. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - House dust mite allergy is tied to respiratory symptoms and long-term allergy management, so market growth points to stronger demand for testing, symptom relief and preventive care. - The market’s expansion also reflects rising allergic disease burden and more attention on home-based and personalized treatment options.

What happened: - The Business Research Company projected the global house dust mite allergy market will rise from $2.37 billion in 2025 to $2.7 billion in 2026. - The company forecast the market will reach $4.62 billion by 2030. - The forecast implies a 14.3% compound annual growth rate from 2025 through 2030. - The report said North America held the largest market share in 2025. - The report said Asia-Pacific will be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offered a free sample of the market report. - The company also made the full house dust mite allergy market report available.

The details: - The report linked historical growth to higher prevalence of allergic conditions, greater awareness of respiratory allergies, wider access to diagnostic testing, increased use of antihistamine medications and improvements in allergy treatment. - The forecast growth is driven by more personalized immunotherapy, stronger focus on preventive allergy care, growth in home-based allergy management solutions, demand for long-term symptom control and advances in biologic allergy therapies. - Trends highlighted in the report include wider use of immunotherapy, greater acceptance of sublingual allergy tablets, broader early diagnostic testing and more personalized allergy management strategies. - House dust mite allergy refers to allergic reactions triggered by tiny insects commonly found in household dust. - Typical symptoms include sneezing and other allergy-related issues. - Treatments are aimed at relieving those reactions. - The report said broader awareness of the condition supports demand for related healthcare products and services.

Between the lines: - Asthma is a major demand driver because both asthma and house dust mite allergy involve respiratory inflammation and sensitivity to allergens. - Rising environmental pollution can worsen airway inflammation, which may increase demand for products that reduce allergen exposure and support respiratory health. - The market’s growth trajectory suggests allergy care is shifting from short-term symptom relief toward longer-term management and prevention. - In June 2025, the American Lung Association said adult asthma prevalence in 2023 ranged from 7.1% in Mississippi to 14.1% in Puerto Rico.

What's next: - The market is expected to keep expanding through 2030 at the same 14.3% CAGR. - The report points to more use of biologic therapies and sublingual allergy tablets as key future developments. - Early diagnostic testing and personalized treatment strategies are likely to play a larger role in market growth. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis.

The bottom line: - House dust mite allergy is moving into a higher-growth phase, with treatment innovation, rising asthma prevalence and wider diagnostics all supporting a market that could nearly double by 2030.